Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib

Conditions: Non-squamous NSCLC With Completely Resectable (Stage II-III) Disease With Epidermal Growth Factor Receptor (EGFR) Mutation Interventions: Drug: Osimertinib Sponsors: Jair Bar, M.D., Ph.D. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials